Affiliated Sites
  • Clinicians Network Payer Bioinformatics
Be The Match

Javascript disabled. This site requires JavaScript How to enable JavaScript.

You are using an outdated browser. Please upgrade your browser to improve your experience.

Close

NMDP

Be The Match
  • About Us
  • E-News Sign Up
  • My Cart
  • Transplant Indications and Outcomes
    • HLA Today
    • Disease-Specific Indications and Outcomes
      • AML - Adult
      • AML - Pediatric
      • ALL - Adult
      • ALL - Pediatric
      • Myelodysplastic Syndromes (MDS)
      • CML
      • CLL
      • NHL
      • Hodgkin Lymphoma
      • Multiple Myeloma
      • Severe Aplastic Anemia & Marrow Failure
      • Sickle Cell Disease
      • Immune Deficiency Diseases
      • Inherited Metabolic Disorders
      • Thalassemia
      • Other Diseases
      • Myeloproliferative Neoplasms
    • Additional Outcomes
      • Unrelated vs. Sibling Donor Outcomes
      • Older Patient Outcomes
      • Timing Impact on Outcomes
    • Eligibility
    • Referral Timing Guidelines
    • Order Kits
    • HLA Typing for Family Members
  • Transplant Therapy and Donor Matching
    • Cell Sources
    • HLA Typing and Matching
    • Donor or Cord Blood Search Process
      • Likelihood of Finding a Match
      • Preliminary Search Request
    • Jason Carter Clinical Trials Program
  • Post-Transplant Care
    • Early Complications
    • Vaccinations
    • Long-Term Care Guidelines
      • Pediatric Considerations
    • Chronic GVHD
      • Skin
      • Nails
      • Scalp and Body Hair
      • Eyes
      • Mouth
      • Lungs
      • Muscles, Fascia, Joints
      • Hematopoietic & Immune
      • GI Tract
      • Liver
      • Genitalia
      • Other
    • Post-Transplant Guidelines
  • Medical Education & Research
    • Browse News
    • Browse Research
      • Mismatched donor sources may fill an unmet need for patients without fully matched family or unrelated donors
      • Hematopoietic cell donor type may not impact quality of life post-transplant
      • Novel three-drug combination improves GVHD-free and relapse-free survival and relapse after allogeneic transplant
      • Long-term risks of hematological malignancy, autoimmune or thrombotic events do not differ in bone marrow and filgrastim-mobilized PBSC donors
      • Socioeconomic status but not race and ethnicity is likely associated with chronic GVHD outcomes after allogeneic HCT
      • Linkage across research databases may provide a more complete understanding of HCT patient outcomes
      • Race and ethnicity matching may not impact umbilical cord blood transplant patient outcomes
      • Factors associated with young adults opting out of donation for HCT may provide insights into donor availability
      • Alternative donor HCT may yield comparable outcomes and expand access for myelofibrosis patients
      • Younger matched unrelated donors may reduce relapse risk after allogeneic HCT compared to using older matched sibling donors
      • Allogeneic HCT may be a better option for older patients with AML than conventional consolidation therapy
    • Education Catalog
      • State of the Science in Ensuring a Donor for All
      • Predicting and Addressing Relapse After HCT
      • After the Results Quality of Life Pre- and Post-Transplant
      • Overcoming Challenges in Cell and Gene Therapy Trials Part 2
      • Overcoming Challenges in Cell and Gene Therapy Trials Part 1
    • Materials Catalog
    • HCT Presentation Slides
    • About Our Research
    • Transplant Enews
  • Resources
    • Patient Resources
    • Financial Resources
    • Obstetrician Resources
    • Technique Videos
    • Umbilical Cord Blood Collection Training for Public Donation
    • Local Provider Partnership Program
  • Browse News
  • Browse Research
  • Education Catalog
  • Materials Catalog
  • HCT Presentation Slides
  • About Our Research
  • Transplant Enews

Education Catalog

  • State of the Science in Ensuring a Donor for All
  • Predicting and Addressing Relapse After HCT
  • After the Results Quality of Life Pre- and Post-Transplant
  • Overcoming Challenges in Cell and Gene Therapy Trials Part 2
  • Overcoming Challenges in Cell and Gene Therapy Trials Part 1
  • Medical Education & Research
  • Education Catalog
  • The Evolution of HCT Self-Paced Learning Course
  • Email
  • Print This Page

The Evolution of HCT Self-Paced Learning Course

Earn up to 4.25 CME/CE credits in this five-part series

Community hematology/oncology practices play a critical role to expand patient access to hematopoietic cell transplantation (HCT) and improve patient outcomes. This five-part self-paced learning course will help you better understand the current state of the science for HCT and cell therapy by following the evolution of HCT and addressing common misconceptions.

You’ll gain a better understanding of barriers to consultation at a transplant center and resources available to hematology/oncology practices to help overcome those barriers.

Modules in the five-part course include:

  • Part 1: HCT Basics and Outcomes (1.5 CME/CE credits)
  • Part 2: Eligibility for Transplant (0.75 CME/CE credits)
  • Part 3: Donor Availability (0.75 CME/CE credits)
  • Part 4: Addressing Barriers to HCT (0.5 CME/CE credits)
  • Part 5: Shared Care (0.75 CME/CE credits)

Take the course as you have time but complete all five modules within six months for the best learning experience. The National Marrow Donor Program® (NMDP)/Be The Match® developed this free CME/CE course with content approval by physicians from the American Society for Transplantation and Cellular Therapy (ASTCT).

Target Audience

Community hematologists/oncologists, hematology/oncology advanced practice providers, and BMT fellows at transplant centers

Part 1: HCT Basics and Outcomes

CREDITS: 1.5 CME/CE
Access Part 1: HCT Basics and Outcomes

Part 1 lays the groundwork for the rest of the course. This module covers the basics of HCT, including the role of HLA, the evolution of HCT, and commonly held HCT misperceptions and concerns.

Then, you’ll delve into major advances in HCT outcomes over time. You’ll learn about survival improvements, graft-versus-host disease (GVHD) prevention advances and patient quality of life.

Finally, you’ll explore patient outcomes for major disease categories covered in the NMDP/Be The Match-ASTCT HCT Consultation Timing Guidelines and get access to the guidelines.

Start Part 1

Part 2: Eligibility for Transplant

CREDITS: 0.75 CME/CE
Access Part 2: Eligibility for Transplant

Part 2 covers advances that have expanded patient eligibility for HCT. This module explains why chronological age is no longer a barrier to HCT and how transplant teams assess and address patient comorbidities.

You’ll gain a better understanding of the role of measurable residual disease as a consideration for HCT. Finally, you’ll explore innovations in cell therapy and learn about the relationship between HCT and CAR-T therapy.

Start Part 2

Part 3: Donor Availability

CREDITS: 0.75 CME/CE
Access Part 3: Donor Availability

Part 3 dispels the myth that certain patients won’t have a donor option for HCT, particularly patients who are racially or ethnically diverse. This module explores how alternative stem cell sources and advances in mismatched donor HCT expand patient access to transplant.

You’ll also learn how donor search optimization and modeling techniques can aid in clinical decision making.

Start Part 3

Part 4: Addressing Barriers to HCT

CREDITS: 0.5 CME/CE
Access Part 4: Addressing Barriers to HCT

Part 4 examines major barriers to HCT and ways to help patients overcome those barriers. This module reviews psychosocial barriers and access challenges in HCT as well as trends in racial and ethnic disparities in HCT.

You’ll also take a close look at the role the community hematologist/oncologist plays in patient access to HCT and explore disconnects between physician perceptions and evidence-based indications for HCT consultation.

Start Part 4

Part 5: Shared Care

CREDITS: 0.75 CME/CE
Access Part 5: Shared Care

Part 5 explores how shared and coordinated care between hematology/oncology practices and transplant centers can help overcome barriers to HCT, optimize the patient experience and improve patient outcomes. You’ll discover how coordinated care can help patients receive HCT at the optimal time and receive the best possible care after transplant once the patient leaves the transplant center.

You’ll also learn how coordinated care can improve patient access to clinical trials and other treatment options, whether or not the patient receives a transplant.

Start Part 5

Ready to keep learning and earn more CME/CE credit?

Take our CME course, Setting Up Patients for HCT and Cellular Therapy Success (1.0 CME/CE credit). You’ll receive practical recommendations and resources on how to successfully introduce transplant and cell therapy options to your patients and coordinate with your transplant center.

Access course details


These activities are certified by Medical Learning Institute, Inc. for physicians and nurses.

  • Email
  • Print This Page

Transplant Indications and Outcomes

  • HLA Today
  • Disease-Specific Indications and Outcomes
  • Additional Outcomes
  • Eligibility
  • Referral Timing Guidelines
  • Order Kits
  • HLA Typing for Family Members

Transplant Therapy and Donor Matching

  • Cell Sources
  • HLA Typing and Matching
  • Donor or Cord Blood Search Process
  • Jason Carter Clinical Trials Program

Resources

  • Patient Resources
  • Financial Resources
  • Obstetrician Resources
  • Technique Videos
  • Umbilical Cord Blood Collection Training for Public Donation
  • Local Provider Partnership Program

Contact Us

National Marrow Donor Program —
Entrusted and under contract to operate the C.W. Bill Young Cell Transplantation Program, including Be The Match Registry®.
Copyright © 1996-2023 National Marrow Donor Program. All Rights Reserved. Terms of Use | Privacy Policy | Trademark & Copyright